Comparative Pharmacology
Head-to-head clinical analysis: EMFLAZA versus KENALOG 40.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMFLAZA versus KENALOG 40.
EMFLAZA vs KENALOG-40
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Agonist at glucocorticoid receptors, modulating gene expression to suppress inflammation and immune response.
Corticosteroid with anti-inflammatory, immunosuppressive, and antiproliferative properties; suppresses cytokine production, inhibits phospholipase A2, reduces prostaglandin and leukotriene synthesis, and stabilizes lysosomal membranes.
0.6 mg/kg orally once daily (maximum 60 mg/day); titrate to lowest effective dose based on clinical response.
Intra-articular injection: 10-40 mg for large joints, 5-15 mg for medium joints, 2.5-5 mg for small joints. Intralesional injection: 2.5-5 mg per lesion. Intramuscular injection: 40-80 mg once monthly. Not for IV or subcutaneous use.
None Documented
None Documented
6.2 hours (range 4.5–8.1 h) in healthy adults; prolonged in hepatic impairment.
Terminal elimination half-life is approximately 2 to 3 hours after IV administration, but due to the triamcinolone acetonide suspension formulation, the effective half-life following intramuscular or intra-articular administration is prolonged to 2-3 weeks due to slow dissolution from the injection site.
Renal excretion of inactive metabolites; less than 5% excreted as unchanged drug in urine. Biliary/fecal elimination accounts for <1%.
Primarily hepatic metabolism followed by renal excretion of inactive metabolites. Less than 5% excreted unchanged in urine. Biliary/fecal elimination accounts for approximately 15-20% of total clearance.
Category C
Category C
Corticosteroid
Corticosteroid